Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.

A specific plan recognized by all relevant parties could not be formed.

wallstreetcnJan 7 03:23 ET

Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.

① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.

cls.cnJan 6 10:59 ET

The final chapter of the litigation battle between the two state-owned enterprises in Nanjing: Soho Holly Corporation's compensation is determined, with profits expected to decrease by over 30 million in 2024.|Quick read announcement.

① The judgment of the second instance (final judgment) of the lawsuit between Soho Holly Corporation and Nanjing Business & Tourism Corp., Ltd. is to reject the appeal and uphold the original ruling, with the former paying the latter 22.122 million yuan in goods payment and penalty; ② Both parties are state-owned enterprises and located relatively close to each other, but the litigation dispute has been prolonged, originating from a contract fraud committed by Soho Holly Corporation employees; ③ Soho Holly Corporation stated that this matter will impact the company's profit and loss for the year 2024, with the estimated amount being approximately 30.17 million yuan.

cls.cnJan 6 08:52 ET

As the Spring Festival holiday approaches, the tourism Industry is expected to pick up, and these Concept stocks are frequently being investigated.

The Spring Festival holiday is from January 28 to February 4, 2025, totaling 8 days.

cls.cnDec 19, 2024 19:45 ET

Jinyu bio-technology: The industry is in the lowest point in history. New products next year will contribute to revenue growth | Direct coverage of the earnings conference.

① At the performance briefing, the chairman of jinyu bio-technology, Zhang Chongyu, admitted that the industry is currently at its lowest point in history; ② The company stated that competition in the pig vaccine market is fierce, and it will maintain its existing market share. Several new vaccines will be launched in the next two years, and it is expected that the new products will contribute a certain revenue increment next year.

cls.cnNov 28, 2024 05:50 ET

It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.

①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.

cls.cnOct 18, 2024 01:13 ET